Tonix Pharmaceuticals Holding Corp. (TNXP)
Chart Events
Performance Outlook
| Previous Close | 1.1600 |
| Open | 1.1500 |
| Bid | 1.1700 x 39400 |
| Ask | 1.1800 x 1100 |
| Day's Range | 1.1400 - 1.2350 |
| 52 Week Range | 0.5100 - 2.4600 |
| Volume | 9,384,578 |
| Avg. Volume | 39,066,783 |
| Market Cap | 382.223M |
| Beta (5Y Monthly) | 1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5520 |
| Earnings Date | May 10, 2021 - May 14, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.88 |
Fair Value
Related Research
- Motley Fool
Robinhood Investors Are Buying Tonix Pharmaceuticals Stock. Should You?
You've probably heard of most of the 100 most popular stocks on Robinhood. With the small biotech recently making it onto the most popular list, Robinhood investors are clearly buying the company's stock.
- GlobeNewswire
Tonix Pharmaceuticals to Present at Needham Virtual Healthcare Conference
CHATHAM, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present a company overview during the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:00 a.m. ET. Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the Needham conference coordinator. A webcast of the presentation will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com. Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL1, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the third quarter of 20212 and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix’s lead vaccine candidate, TNX-18003, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-8013, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox. 1TNX-102 SL is an investigational new drug and has not been approved for any indication.2Pending agreement from FDA on statistical analysis plan.3TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2021, and periodic reports filed with the SEC on or after the date thereof. All Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Contacts Jessica Morris (corporate)Tonix Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 904-8182 Olipriya Das, Ph.D. (media)Russo PartnersOlipriya.Das@russopartnersllc.com(646) 942-5588 Peter Vozzo (investors)Westwicke/ICRpeter.vozzo@westwicke.com(443) 213-0505
- Zacks Small Cap Research
TNXP: Positive Efficacy Data for COVID-19 Vaccine in Non-Human Primates…
By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update TNX-1800 Shows Efficacy in Non-Human Primates On March 17, 2021, Tonix Pharmaceutical Holdings Corp. (NASDAQ:TNXP) announced positive efficacy results for TNX-1800, the company’s lead COVID-19 vaccine, in non-human primates. The study was designed to compare TNX-1800 (modified horsepox virus encoding SARS-CoV-2
